About AVT
Browse Articles
Customer Services


Mathematical modelling of HCV infection: what can it teach us in the era of direct-acting antiviral agents?

Anushree Chatterjee, Jeremie Guedj, Alan S Perelson

Corresponding author name: Alan S Perelson
Corresponding author e-mail: asp@lanl.gov

Citation: Antiviral Therapy 2012; 17:1171-1182
doi: 10.3851/IMP2428

Date accepted: 27 March 2012
Date published online: 05 October 2012


HCV infection is a major cause of chronic liver disease and affects nearly 170 million people worldwide. Whereas the previous standard of care with pegylated interferon and ribavirin had a modest effectiveness, the recent approval of two highly potent protease inhibitors and the ongoing development of dozens of direct-acting antiviral agents (DAAs) constitute a major milestone for HCV therapy. Mathematical modelling of viral kinetics under treatment has played an instrumental role in improving our understanding of virus pathogenesis and in guiding drug development. Here, we review the current state of HCV kinetic modelling, and challenges to the standard biphasic viral decline model that arise when fitting viral kinetic models to data obtained with DAAs.


Copyright © 2020 Nucleus Holdings Ltd. Part of Nucleus Global.
Design and Technology by Nucleus Global
Company registration No. 321 0712 (England & Wales). Registered Office address: Admiral House 76-78 Old Street, London EC1V 9AZ.